Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

Journal of Viral Hepatitis

Volumn 8, Issue 1, 2001, Pages 48-62

  Thevenot T ^a   Regimbeau, C ^a,b   Ratziu, V ^a,b   Leroy, V ^a   Opolon, P ^a   Poynard, T ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

Acute hepatitis C; Chronic hepatitis C; Interferon; Meta analysis; Randomized trials

Indexed keywords

PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; VIRUS RNA;

ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS HEPATITIS;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RNA, VIRAL;

EID: 0035147384     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00271.x     Document Type: Article

References (86)

1. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C
2. Meta-analysis of randomized controlled trials
3. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of Medlar's and manual methods
4. Methods of combining randomized clinical trials: Strengths and limitations
5. Meta-analysis in clinical trials
6. Evaluation de la qualité méthodologique des essais thérapeutiques randomisés
7. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
8. Treatment of chronic hepatitis C with recombinant interferon alfa
9. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
10. Terapia dell'epatite cronica non-A non-B con alfa-2b interferone. Studio clinico controllato e follow-up a lungo termine
11. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
12. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis
13. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis
14. Alpha-interferon treatment of chronic hepatitis C. A controlled, multicentre, prospective study
15. Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia
16. Treatment of chronic hepatitis C with recombinant human interferon alpha-2a: Results of a randomized controlled clinical trial
17. A randomized controlled trial of recombinant interferon alpha in chronic hepatitis C in hemophiliacs
18. Treatment of chronic sporadic-type non-A non-B hepatitis with lymplloblastoid interferon: Gamma GT levels predictive for response
19. Long-term titrated recombinant interferon-α2a in chronic hepatitis C. A randomized controlled trial
20. α-Interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers
21. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha interferon in comparison with a control group
22. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C. A randomized controlled trial
23. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience
24. Fixed versus titrated interferon-α2b in chronic hepatitis C. A randomized controlled multicenter trial
25. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis
26. Interferon alfa treatment of HCV RNA carriers with persistently normal transferase levels: A pilot randomized controlled study
27. A double-blind controlled trial of recombinant interferon-α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels
28. Randomised trial of effect of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
29. A randomised controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus
30. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis
31. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
32. The efficacy of prophylactic interferon-alfa-2b in preventing recurrent hepatitis C after liver transplantation
33. The effect of interferon on the liver in chronic hepatitis C a quantitative evaluation of histology by meta-analysis
34. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C
35. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
36. A controlled study to determine the optimal dose regimen of interferon-α2b in chronic hepatitis C
37. Farrel G for the Australian Hepatitis C Study Group Interferon alfa-2b for chronic hepatitis C. Effects of dose increment and duration of treatment on response rates
38. High-dose interferon therapy in patients with chronic hepatitis C. Biochemical, virological and histological evaluation of two different doses
39. Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter randomized open-label trial
40. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C
41. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: Comparison of 3 or 6 MU for 1 year
42. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C
43. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C
44. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C. Influence on the levels of ALT, viremia and histological activity
45. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C
46. Viral and host factors hat contribute to efficacy of interferonα2a therapy in patients with chronic hepatitis C
47. New approach to HCV treatment. Recognition of disease proces as systemic viral infection rather than as liver disease
48. Comparative efficacy of a high or low dose of interferon (2b in chronic hepatitis C. A randomized controlled trial
49. Recombinant interferonα2a for treatment of chronic hepatitis C. Results of a multicenter randomized controlled dose study
50. A dose-dependent controlled trial of human lymphoblastoid interferon α for genotype 1b chronic hepatitis C associated with high HCV-RNA levels
51. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
52. Comparison of high initial and fixed-dose regimens of interferon-α2a in chronic hepatitis C. A randomized controlled trial
53. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b
54. Comparative efficacy of interferon alfa in cirrhotic ans noncirrhotic patients with non-A, non-B, C hepatitis
55. A comparison of three interferon alfa-2b regimens for long-term treatment of chronic non-A, non-B hepatitis
56. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
57. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C. A multicenter randomized controlled trial
58. 1 interferon for 6 vs 12 months
59. Reinforced regimen of interferon-α2a reduces the incidence of cirrhosis in patients with chronic hepatitis C. A multicentre randomised trial
60. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus
61. A prospective, randomized trial comparing interferon alfa 2a as therapy for chronic hepatitis C
62. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
63. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
64. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C
65. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose
66. Response to higher doses of interferon alfa-2a in patients with chronic hepatitis C. A randomised multicenter trial
67. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon-α-2b for chronic hepatitis type C
68. Chronic hepatitis C. What treatment for nonresponders to recombinant interferon-α
69. Dose increase augments response rate to interferon-α in chronic hepatitis C
70. Highdose interferon-α-2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C
71. Efficacy of interferon dose and prediction of response in chronic hepatitis C. Benelux study in 336 patients
72. Interferon-alpha in acute post transfusion hepatitis C. A randomized, controlled trial
73. A report on therapy of interferon alfa 2b in patients with acute hepatitis C
74. A multicenter randomized controlled trial of recombinant interferon alpha-2b in patients with acute transfusion-associated hepatitis C
75. A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
76. Natural beta interferon in acute type-C hepatitis patients: A randomized controlled trial
77. Effect of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
78. Resolution of acute hepatitis C after therapy with natural beta interferon
79. Interferon as treatment for acute hepatitis C. A Meta-Analysis
80. Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis
81. Outcome of acute hepatitis C and role of alpha interferon therapy
82. 2b traetment prevents chronicity in acute hepatitis C. A pilot study
83. Interferon alfa-2b and ribavirin in treatment-naive patients with chronic hepatitis C and normal ALT levels
84. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus?
85. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
86. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C